Durable ventricular assist device support for failing systemic morphologic right ventricle: Early results

Ed Peng, John J. O'Sullivan, Massimo Griselli, Chandrika Roysam, David Crossland, Milind Chaudhari, Neil Wrightson, Tanveer Butt, Gareth Parry, Guy A. Macgowan, Stephan Schueler, Asif Hasan

Research output: Contribution to journalArticlepeer-review

37 Scopus citations


Background The systemic morphologic right ventricle (RV) in congenitally corrected transposition of the great arteries or after atrial switch for transposition of the great arteries is associated with late ventricular failure. Although the role of the left ventricular assist device (LVAD) in supporting the failing LV is established, the indications and outcomes of using LVAD in a systemic RV remain unclear. We assessed the role of a third-generation LVAD for systemic RV support.

Methods Seven patients (mean age, 36 years) received the HeartWare (HeartWare International Inc, Framingham, MA) VAD for systemic RV failure (congenitally corrected transposition of the great arteries in 1 and after atrial switch in 6). Four patients (57%) had severe subpulmonic LV failure, and aggressive perioperative diuresis with or without hemofiltration was used to offload the subpulmonic LV. The indications of VAD were (1) bridge to transplant in 3 and (2) bridge to decision for a high transpulmonary gradient in 4. Transplantation outcome was compared with systemic RV failure without VAD bridge in 19 patients (years 1989 to 2013).

Results Systemic RV support alone was achieved in all patients, with no early deaths (≤30 days). Overall, 6 (86%) returned home, 3 (44%) received a transplant, 2 (28%) died of noncardiac causes, and 2 (28%) continue on VAD support (median support, 232 days). Repeat catheterization (n = 4) showed an improved median transpulmonary gradient in 3 patients (median 18.5 mm Hg pre-VAD vs 8.0 mm Hg post-VAD). Two bridge-to-decision patients received transplants at 640 and 685 days. The stroke rate on VAD support was 43% (2 thromboembolic and 1 hemorrhagic; 3 with satisfactory recovery). De novo aortic regurgitation was 29% (n = 2; 1 valve replacement). All patients (n = 3) survived transplantation (vs 10.5% early mortality without VAD bridge; p = 1.00) and were well at follow-up (range, 53 to 700 days).

Conclusions The third-generation VAD provides durable support for systemic RV failure as a bridge to transplant and as a strategy to reduce pulmonary vascular resistance. Although concomitant subpulmonic LV failure is common, systemic RV support alone was achieved in all patients.

Original languageEnglish (US)
Pages (from-to)2122-2129
Number of pages8
JournalAnnals of Thoracic Surgery
Issue number6
StatePublished - Dec 1 2014
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2014 The Society of Thoracic Surgeons.


Dive into the research topics of 'Durable ventricular assist device support for failing systemic morphologic right ventricle: Early results'. Together they form a unique fingerprint.

Cite this